Takeda Pharmaceuticals International, Inc., a
wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today
announced that its Pharmaceutical Development Division has entered into
strategic partnerships with Covance and Quintiles, two of the world’s largest
full-service contract research organizations.
Under terms of the agreements, Covance and Quintiles will
work in close partnership with Takeda to plan and execute global development programs
to support new compounds in all therapeutic areas, except oncology. Takeda will
have access to the clinical development capabilities and central laboratory
services of Covance and Quintiles, with each partner company providing
dedicated resources to support Takeda’s development pipeline. Takeda intends to
use a global program-level sourcing strategy to increase operational efficiency.
Through these relationships, Takeda will move toward a fully
virtual outsourcing model combining the expertise and capabilities of Takeda with
those of Covance and Quintiles to improve productivity and facilitate Takeda’s
global growth.
“Takeda is focused on growing its global drug
development footprint, especially in Asia,
while at the same time ensuring quality and increasing efficiency of our
operations,” said Robert Ahlbrandt, Ph.D., senior vice president, global
development operations for Takeda’s Pharmaceutical Development Division.
“Our new strategic partnerships with Covance and Quintiles will improve
the agility and productivity of our drug development activities, helping us to
deliver innovative new medicines to patients globally.”
